These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Trabzuni D; Famulski KS; Ahmad M Biochem J; 2000 Sep; 350 Pt 2(Pt 2):505-10. PubMed ID: 10947965 [TBL] [Abstract][Full Text] [Related]
3. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Seol DW; Li J; Seol MH; Park SY; Talanian RV; Billiar TR Cancer Res; 2001 Feb; 61(3):1138-43. PubMed ID: 11221844 [TBL] [Abstract][Full Text] [Related]
4. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619 [TBL] [Abstract][Full Text] [Related]
5. The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Kim MH; Billiar TR; Seol DW Biochem Biophys Res Commun; 2004 Sep; 321(4):930-5. PubMed ID: 15358116 [TBL] [Abstract][Full Text] [Related]
6. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate. Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307 [TBL] [Abstract][Full Text] [Related]
7. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Mongkolsapaya J; Grimes JM; Chen N; Xu XN; Stuart DI; Jones EY; Screaton GR Nat Struct Biol; 1999 Nov; 6(11):1048-53. PubMed ID: 10542098 [TBL] [Abstract][Full Text] [Related]
9. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094 [TBL] [Abstract][Full Text] [Related]
10. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138 [TBL] [Abstract][Full Text] [Related]
11. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279 [TBL] [Abstract][Full Text] [Related]
12. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
13. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
14. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660 [TBL] [Abstract][Full Text] [Related]
16. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Sun SY; Yue P; Hong WK; Lotan R Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424 [TBL] [Abstract][Full Text] [Related]
17. Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity. Kim YH; Lee YJ J Cell Biochem; 2006 Aug; 98(5):1284-95. PubMed ID: 16514644 [TBL] [Abstract][Full Text] [Related]
18. Stabilization of TRAIL, an all-beta-sheet multimeric protein, using computational redesign. van der Sloot AM; Mullally MM; Fernandez-Ballester G; Serrano L; Quax WJ Protein Eng Des Sel; 2004 Sep; 17(9):673-80. PubMed ID: 15486023 [TBL] [Abstract][Full Text] [Related]
19. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis. Mori E; Thomas M; Motoki K; Kataika S FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041 [TBL] [Abstract][Full Text] [Related]
20. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]